

ifa

UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of )  
Cooper et al. )  
Serial No.: 10/525,345 )  
Filed: August 20, 2003 )  
For: Dosage Forms and Related Therapies )



Group Art Unit: 1615  
Examiner: Unknown  
Confirmation No.: 3912  
Customer No.: 53897

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed prior to the first office action on the merits of the above-captioned application, thus, it is believed that no fee is due in connection with this submission. However, if it is determined that a fee is due, the Commissioner is hereby authorized to charge the requisite fee, or any fees that may be due in connection with this and the attached papers, or with this application during its entire pendency, or to credit any overpayment, to Deposit Account No. 04-1679.

In accordance with 37 C.F.R. §1.56 and 37 C.F.R. §§1.97-1.98, this Information Disclosure Statement, including Form PTO/SB/08 (3 pages), and cited documents, is provided herewith.

CERTIFICATE OF MAILING

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

April 20, 2006  
Date of Deposit

R.P. Ippolito  
Roxanne Ippolito

Applicant would also like to cross-reference the following U.S. and International applications:

<u>U.S. App. Serial. No.</u>	<u>Filing Date</u>	<u>Pub. No.</u>	<u>Pub. Date</u>
09/671,967	09/27/2000	6,348,465	02/19/2002
09/818,344	03/26/2001	6,855,511	02/15/2005
09/975,751	10/10/2001	6,610,693	08/26/2003
10/226,685	08/22/2002	6,897,243	05/24/2005
10/388,213	03/12/2003	2003/0203973	10/30/2003
10/388,213	03/12/2003	6,951,890	10/04/2005
11/184,761	07/19/2005	2006/0041170	02/23/2006
11/018,720	12/20/2004	2005/0159364	07/21/2005
11/221,298	09/07/2005	2006/0009534	01/12/2006
09/745,078	12/20/2000	20030050434	03/13/2003
10/374,624	02/24/2003	2003/0166561 A1	09/04/2003
10/632,366	07/13/2003	2004/0142393 A1	07/22/2004
10/306,645	11/26/2002	2004/0038861 A1	02/26/2004
11/023,827	12/28/2004	2005/0159489 A1	07/21/2005
11/018,720	12/20/2004	2005/0159364 A1	07/21/2005
10/114,540	04/01/2002	6,884,575	04/26/2005
10/964,870	10/14/2004	2005/0047998 A1	03/03/2005
10/349,326	01/21/2003	2004/0023854 A1	02/05/2004
10/378,544	03/03/2003	2005/0074756 A1	04/07/2005
10/354,893	01/29/2003	2003/0186946 A1	10/02/2003
11/297,169	12/08/2005		


<u>International App. No.</u>	<u>Filing Date</u>	<u>Pub. No.</u>	<u>Pub. Date</u>
PCT/NZ99/00161	09/24/1999	WO 00/18392	04/06/2000
PCT/NZ99/00160	09/24/1999	WO 00/18891	04/06/2000
PCT/NZ03/00043	03/10/2003	WO 03/075910	09/18/2003
PCT/NZ03/00042	03/10/2003	WO 03/077901	09/25/2003
PCT/NZ03/00047	03/17/2003	WO 04/017957	03/04/2004
PCT/NZ03/00184	08/20/2003	WO 04/017956	03/04/2004
PCT/NZ04/000325	12/20/2004	WO 05/058294	6/30/2005
PCT/NZ00/00102	06/19/2000	WO 00/78805	6/19/2000
PCT/NZ03/00168	07/31/2003	WO 04/012760	2/12/2004
PCT/NZ02/00262	11/26/2002	WO 03/045424	6/05/2003
PCT/IB02/02488	04/01/2002	WO 02/079785	10/10/2002
PCT/NZ03/00002	01/17/2003	WO 03/062275	07/31/2003
PCT/NZ03/00039	03/03/2003	WO 03/074559	09/12/2003
PCT/NZ03/00009	01/29/2003	WO 03/063880	08/07/2003
PCT/US03/02732	01/29/2003		
PCT/US03/00074	01/03/2003	WO 03/057719	07/17/2003
PCT/IB03/006187	01/21/2003	WO 04/056861	07/08/2004
PCT/IB05/052421	07/19/2005	WO 06/027705	03/16/2006
PCT/NZ2005/000337	Dec 20/2005		

The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 C.F.R. §1.56. The filing of this Information Disclosure Statement is not an admission by Applicants or Applicants' representatives that any of the documents, singly or in any combination, is effective as prior art against the subject application. Additionally, in accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists in addition to those submitted herewith.


Applicants respectfully request that the Examiner review the foregoing documents and information and that they be made of record in the file history of the subject application.

Respectfully submitted,

By: \_\_\_\_\_

  
James W. Collett, Ph.D.  
Reg. No. 46,636

DUANE MORRIS LLP  
101 West Broadway, Suite 900  
San Diego, CA 92101-8285  
(O) (619) 744-2200  
(F) (619) 744-2201



Substitute Form PTO/SB/08

U.S. Department of Commerce  
Patent and Trademark Office

Attorney's Docket No.

E3691-00102

Application No.

10/525,345

**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

Applicant

Cooper et al.

Filing Date

August 20, 2003

Group Art Unit

1615

(37 CFR § 1.98(b))

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	4323558	04/06/1982	Nelson			
	AB	5366505	11/22/1994	Farber			
	AC	5420120	05/30/1995	Boltralik			
	AD	5824049	10/20/1998	Ragheb et al.			
	AE	5906996	05/25/1999	Murphy			
	AF	6309380	10/30/2001	Larson et al.			
	AG	2003/0013772	01/16/2003	Murphy et al.			
	AH	2003/0055003	03/20/2003	Bar-Or et al.			
	AI	2003/0055113	03/20/2003	Wang et al.			
	AJ	6576672	06/10/2003	Murphy			
	AK	2003/0139312	07/24/2003	Caswell			
	AL	2003/0232799	12/18/2003	Wang et al.			
	AM	2004/0019087	01/29/2004	Ternansky et al.			
	AN	2004/0076603	04/22/2004	Peled et al.			
	AO	2004/0259945	12/23/2004	Brewer et al.			
	AP	2005/0002876	01/06/2005	Yukl et al.			
	AQ	2005/0009760	01/13/2005	Wang et al.			
	AR	2005/0031651	02/10/2005	Gervais et al.			
	AS	2005/0085555	04/21/2005	Murphy et al.			

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AT	02/43722	06/06/2002	WIPO				
	AU	03/099223	12/04/2003	WIPO				
	AV	1234585	08/28/2002	Europe				
	AW							

Examiner Signature  
/June Rogers/

Date Considered

05/27/2008

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO/SB/08)

DM2168895.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.R./

Substitute Form PTO/SB/08 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3691-00102	Application No. 10/525,345
		Applicant Cooper et al.	
		Filing Date August 20, 2003	Group Art Unit 1615

**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR § 1.98(b))

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AX	R. A. Cherny et al., "Chelation and Intercalation: Complementary Properties in a Compound for the Treatment of Alzheimer's Disease", <i>Journal of Structural Biology</i> , 130, 209-216 (2000)
	AY	S.C. Cunnane et al., "Copper Inhibits Pressor Responses to Noradrenaline but not Potassium. Interactions with Prostaglandins E <sub>1</sub> , E <sub>2</sub> , and I <sub>2</sub> and Penicillamine", <i>Can. J. Physiol. Pharmacol.</i> Vol. 57, 35-40 (1979)
	AZ	Leslie M. Klevay, "Coronary Heart Disease: the Zinc/ Copper Hypothesis" <sup>1,2*</sup> , <i>The American Journal of Clinical Nutrition</i> 28: 764-774 (1975)
	AAA	P. Ou et al., "Activation of Aldose Reductase in Rat Lens and Metal-Ion Chelation by Aldose Reductase Inhibitors and Lipoic Acid", <i>Free Rad. Res.</i> , Vol. 25, No. 4, 337-346, (1996)
	ABB	Vincent M. Monnier, "Transition Metals Redox: Reviving an Old Plot for Diabetic Vascular Disease", <i>The Journal of Clinical Investigation</i> , Vol. 107, No. 7, 799-801 (2001)
	ACC	S. M. Karmazyn et al., "Prostaglandin Concentrations Cause Cardiac Rhythm Disturbances. Effect Reversed by Low Levels of Copper or Chloroquine", <i>Prostaglandins</i> , Vol. 15, (1978)
	ADD	A. Nitenberg et al., "Coronary Artery Response to Physiological Stimuli Are Improved by Deferoxamine but not by L-Arginine in Non-Insulin-Dependent Diabetic Patients With Angiographically Normal Coronary Arteries and No Other Risk Factors", <i>American Heart Association</i> , (1997), XP-002366411
	AEE	S. P. Wolff, "Diabetes Mellitus and Free Radicals", <i>British Medical Bulletin</i> , Vol. 49, No. 3, 642-652, (1993)
	AFF	J. Y. Jeremy et al., "Copper Chelators Inhibit Platelet Thromboxane A <sub>2</sub> Synthesis and Lipoxxygenase Activity, In Vitro", <i>J. Drug Dev Clin Pract</i> 7, 119-126 (1995)
	AGG	N. E. Cameron et al., "Neurovascular Dysfunction in Diabetic Rats", <i>J. Clin. Invest.</i> , Vol. 96, 1159-1163, (1995)
	AHH	N. Shimizu et al., "Treatment and Management of Wilson's Disease", <i>Pediatrics International</i> 41, 419-422, (1999)
	AIL	D. L. Eizirik et al., "I, 10 Phenanthroline, a Metal Chelator, Protects Against Alloxan- but not Streptozotocin-Induced Diabetes", <i>Journal of Free Radicals in Biology &amp; Medicine</i> , Vol. 2, 189-192 (1986)
	AJJ	Z.Y. Jiang et al., "Spirohydantoin Inhibitors of Aldose Reductase Inhibit Iron-and Copper-Catalysed Ascorbate Oxidation in Vitro", <i>Biochemical Pharmacology</i> , Vol. 42, No. 6, 1273-1278 (1991)
	AKK	Y. Toshihiko et al., "Subacute and Chronic Toxicity Studies of Triethylenetetramine Dihydrochloride (TJA-250) by Oral Administration to F-344 Rats" <i>Journal of Toxicological Sciences</i> , Vol. 23, No. 4, 619-642 (1998) Abstract (EP-002356395)
	ALL	M. L. Failla et al., "Hepatic and Renal Metabolism of Copper and Zinc in the Diabetic Rat", <i>American Journal of Physiology</i> , Vol. 244, No. 2, E115-E121 (1983) Abstract (XP-002366428)
	AMM	M. L. Failla et al., "Altered Tissue Content and Cytosol Distribution of Trace Metals in Experimental Diabetes", <i>Journal of Nutrition</i> , Vol. 111, No. 11, 1900-1909 (1981) Abstract (XP-002366429)
	ANN	P. Ou et al., "Erythrocyte Catalase Inactivation (H <sub>2</sub> O <sub>2</sub> production) by Ascorbic Acid and Glucose in the Presence of Aminotriazole: Role of Transition Metals and Relevance to Diabetes", <i>Biochemical Journal</i> , Vol. 303, No. 3, 935-940 (1994) Abstract (XP-002366430)
	AOO	Copy of International Search Report from European Application EP99946470

Examiner Signature /June Rogers/	Date Considered 05/27/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO/SB/08)

DM2/68895 1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.R./

Substitute Form PTO/SB/08 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>E3691-00102</b>	Application No. <b>10/525,345</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant <b>Cooper et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group Art Unit <b>1615</b>

(37 CFR §1.98(b))

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	APP	Copy of International Search Report from European Application EP03792902
	AQQ	Copy of International Search Report from PCT/NZ2004/000325
	ARR	Copy of International Search Report from PCT/NZ2005/000337
	ASS	Copy of International Search Report from EP99946470

Examiner Signature <i>/June Rogers/</i>	Date Considered <b>05/27/2008</b>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO/SB/08)

DM2/688895.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.R./